A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis.

Abstract

Fatigue occurs in a majority of patients with MS and is generally independent of measurable neurologic disability. Few options for treatment are available. We conducted a double-blind, placebo-controlled, crossover trial for each of two 4-week treatment periods. Forty-six eligible patients entered and five dropped out due to concurrent exacerbations. Nineteen patients (46.3%) experienced excellent or good relief of fatigue with pemoline, and eight patients (19.5%) with placebo (p = 0.06, Fisher's exact test). One-fourth of patients did not tolerate the drug well, and 7% had to discontinue pemoline during the study due to side effects. The most common side effects were anorexia, irritability, and insomnia. Pemoline may be an effective short-term treatment for fatigue associated with MS, but its adverse effects are not well tolerated by many patients.

• Authors: B G Weinshenker, M Penman, B Bass, G C Ebers, G P Rice
• Journal: Neurology (Neurology) Vol. 42 Issue 8 Pg. 1468-71 (Aug 1992) ISSN: 0028-3878 [Print] United States
• PMID: 1641137 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Pemoline

Topics

• Adult
• Double-Blind Method
• Fatigue (drug therapy, etiology, physiopathology)
• Humans
• Middle Aged
• Multiple Sclerosis (complications)
• Pemoline (adverse effects, therapeutic use)